SIK2 and pulmonary fibrosis: Additionally, it demonstrates the efficacy and preliminary safety of selectively targeting SIK2 using the inhibitor YKL-06-062 and the repurposed agent fostamatinib in mitigating pulmonary fibrosis in vivo.